All
Daniela Ferrara appointed by Topcon Healthcare as CMO
Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy.
Wave of the future: Partnership between eye care and psychology
A two-way foot bridge between eye care and mental health.
Central choroidal thickness: Important biomarker for assessing response to aflibercept in treatment-naive DME
Brazilian researchers used swept-source OCT and OCT-angiography to study the effects of an initial dose of aflibercept on untreated diabetic macular edema in patients.
When the world went virtual: How ophthalmology’s conferences stayed on track
Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis.
A decade of uveitis: Trends in diagnosis and disease progression
Positive topline results from phase 2 VVN461 trial for non-infectious anterior uveitis
VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, showcasing safety and efficacy.
Eye care industry leaders met at the White House to discuss tariff implications
Industry leaders discuss the impact of rising tariffs on vision care costs, advocating for policy changes to ensure affordable access to essential eyewear.
Prototype Oz system stimulates thousands of M cone cells: On the threshold of new ocular experimentation
Novel color created, olo, beyond previous human perception.
Researchers develop virus-like particle to enhance editing proteins causing inherited eye diseases
The first Retina Sunday program debuts at this year's ASCRS and ASOA Annual Meetings
Abby Markward, MBA, executive director of the ASCRS Foundation and the ASOA, provides a sneak peek of the posterior segment-focused event.
Beth Marsh appointed as new Neurotech chief commercial officer
Marsh will begin her role as COO April 28.
Using retinal images to classify metabolic syndrome
Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”
FDA issues CRL for Regeneron's aflibercept 8 mg (Eylea HD) sBLA
The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.
AI-powered biomarker segmentation enhances precision in monitoring nAMD
Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.
Geographic and institutional disparities identified in DR and DME clinical trials
Results showed an unequal distributions of these clinical trials among rural and low-income populations.
Racial disparities in visual outcomes of ranibizumab-treated DME
The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.
RWC 2025: Companies to share data at meeting in Fort Lauderdale
Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida.
FDA accepts Regeneron's sBLA for Eylea HD as priority review
The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every-4-week dosing across approved indications.
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA
A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.
FDA grants regenerative medicine advanced therapy designation to ATSN-201 for X-linked retinoschisis
Phase I/II safety and efficacy study currently enrolling.
Prevent Blindness announces leadership promotions
As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission.
Biocon, Regeneron settle to launch aflibercept biosimilar, Yesafili in the US
This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.
Effect of social media on follow-up in congenital ectopia lentis
Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.
Eyestem reports promising phase 1 trial results in patients with geographic atrophy
Eyecyte-RPE is a suspension of human induced pluripotent stem cells derived from retinal pigment epithelial cells.
New guidelines boost choriocapillaris imaging in AMD with SS-OCTA
Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.
Jeffrey Nau named CEO of Aviceda Therapeutics
Nau will lead the company in a new phase of growth and innovation.
First patient dosed in Vantage Biosciences' phase 2 study of VX-01 for nonproliferative diabetic retinopathy
VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).
AI label system enhances training accuracy in retinal disease diagnosis
A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education.
Enhanced OCT GA segmentation achieved with new multistage model
Researchers introduce a multistage dual-branch network to improve accuracy and efficiency.
Pykus Therapeutics announces completion of enrollment in PYK-2101 clinical trial
PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.
